62491-96-7

Usage

Uses

Used in Pharmaceutical Industry:
1-(2-Chloro-ethyl)-3-pyridin-4-yl-urea is used as a potential therapeutic agent for its potential anticancer, anti-inflammatory, and antimicrobial properties. 1-(2-CHLORO-ETHYL)-3-PYRIDIN-4-YL-UREA's structure, featuring a pyridine ring and a chloroethyl group, may contribute to its biological activities, making it a candidate for further research and development in the field of medicine.
Used in Research and Development:
1-(2-Chloro-ethyl)-3-pyridin-4-yl-urea is used as a subject of study in scientific research to explore its potential applications in medicine. 1-(2-CHLORO-ETHYL)-3-PYRIDIN-4-YL-UREA's unique structure and potential biological activities make it an interesting candidate for investigating its effects on various diseases and conditions, with the aim of developing new treatments and therapies.

InChI:InChI=1/C8H10ClN3O/c9-3-6-11-8(13)12-7-1-4-10-5-2-7/h1-2,4-5H,3,6H2,(H2,10,11,12,13)

Upstream product

• 504-24-5 4-aminopyridine 
• 1943-83-5 2-chloroethyl isothiocyanate 

Downstream Products

• 52210-90-9 1-(pyridin-4-yl)-2-imidazolidinone 
• 1372097-30-7 (2S)-N-[4-{1-(3-pentoxy)-3-(4-pyridyl)-2-imidazolidinone}-5-methoxy-2-amino benzoyl]pyrrolidine-2-carboxaldehyde diethyl thioacetal 
• 1372097-29-4 (2S)-N-[4-{1-(3-butoxy)-3-(4-pyridyl)-2-imidazolidinone}-5-methoxy-2-amino benzoyl]pyrrolidine-2-carboxaldehyde diethyl thioacetal 
• 1372097-28-3 (2S)-N-[4-{1-(3-propoxy)-3-(4-pyridyl)-2-imidazolidinone}-5-methoxy-2-aminoben-zoyl]pyrrolidine-2-carboxaldehyde diethyl thioacetal 
• 1372097-26-1 (2S)-N-[4-{1-(3-butoxy)-3-(4-pyridyl)-2-imidazolidinone}-5-methoxy-2-nitro-benzoyl]pyrrolidine-2-carboxaldehyde diethyl thioacetal 
• 1372097-25-0 (2S)-N-[4-{1-(3-propoxy)-3-(4-pyridyl)-2-imidazolidinone}-5-methoxy-2-nitro-benzoyl]pyrrolidine-2-carboxaldehyde diethyl thioacetal 

Relevant academic research and scientific papers

Discovery of Potent EV71 Capsid Inhibitors for Treatment of HFMD

Enterovirus 71 (EV71) is a major causative agent of hand, foot, and mouth disease (HFMD), which can spread its infections to the central nervous and other systems with severe consequences. The viral caspid protein VP1 is a well-known target for antiviral efficacy because its occupancy by suitable compounds could stabilize the virus capsid, thus preventing uncoating of virus for RNA release. In this Letter, design, synthesis, and biological evaluation of novel anti-EV71 agents (aminopyridyl 1,2,5-thiadiazolidine 1,1-dioxides) are described. One of the most promising compounds (14) showed excellent antiviral activity against EV71 (EC50 = 4 nM) and exhibited excellent in vivo efficacy in the EV71 infected mouse model.

Synthesis, DNA binding and anticancer activity of pyridylimidazolidinone linked pyrrolo[2,1-c][1,4]benzodiazepine conjugates

A series of pyridylimidazolidinone linked pyrrolo[2,1-c][1,4]benzodiazepine (PBD) conjugates have been synthesized and evaluated for their DNA binding ability and cytotoxicity. These conjugates exhibited significant DNA binding ability and potent anticanc

Design, synthesis, and antipicornavirus activity of 1-[5-(4-arylphenoxy) alkyl]-3-pyridin-4-ylimidazolidin-2-one derivatives

A series of pyridylimidazolidinone derivatives was synthesized and tested in vitro against enterovirus 71 (EV71). On the basis of compound 33 (DBPR103), introduction of a methyl group at the 2- or 3-position of the linker between the imidazolidinone and the biphenyl resulted in markedly improved antiviral activity toward EV71 with IC50 values of 5.0 nM (24b) and 9.3 nM (14a), respectively. Increasing the branched chain to propyl resulted in a progressive decrease in activity, while inserting different heteroatoms entirely rendered the compound only weakly active. The introduction of a bulky group (cyclohexyl, phenyl, or benzyl) led to loss of activity against EV71. The 4-chlorophenyl moiety in 14a was replaced with bioisosteric groups such as oxadiazole (28a-d) or tetrazole (32a,b), dramatically improving anti-EV71 activity and selectivity indices. Compounds 14a, 24b, 28b, 28d, and 32a exhibited a strong activity against lethal EV71, and no apparent cellular toxicity was observed. Three of the more potent imidazolidinone compounds, 14a, 28b, and 32b, were subjected to a large group of picornaviruses to determine their spectrum of antiviral activity.

Synthesis and antipicornavirus activity of (R)- and (S)-1-[5-(4′- chlorobiphenyl-4-yloxy)-3-methylpentyl]-3-pyridin-4-yl-imidazolidin-2-one

The new pyridyl imidazolidinone derivative, 1-[5-(4′-chlorobiphenyl- 4-yloxy)-3-methylpentyl]-3-pyridin-4-yl-imidazolidin-2-one (±)-1a, was synthesized and found to have an excellent antiviral activity against EV71 (IC50 = 0.009 μM). Therefore, both the enantiomers, (S)-(+)-1a and (R)-(-)-1a, have been prepared starting from readily available monomethyl (R)-3-methylglutarate (7) as a useful chiral building block and their antiviral activity was evaluated in a plaque reduction assay. Interestingly, we observed that the enantiomer (S)-(+)-1a was 10-fold more active against enterovirus71 (EV71) (IC50 = 0.003 μM) than the corresponding enantiomer (R)-(-)-1a (IC50 = 0.033 μM). Similar results were found against all five strains (1743, 2086, 2231, 4643, and BrCr) of EV71 tested. This demonstrated that the absolute configuration of the chiral carbon atom at the 3-position of the alkyl linker considerably influenced the anti-EV71 activity of these pyridyl imidazolidinones.

1,3-BENZOTHIAZINONE DERIVATIVES AND USE THEREOF

This invention provides a compound represented by the formula (I) :wherein R1 is a hydrogen atom, a halogen atom, hydroxy, nitro, optionally halogenated alkyl, alkoxy optionally having substituents, acyl or amino optionally having substituents;R2 is pyridyl, furyl, thienyl, pyrrolyl, quinolyl, pyrazinyl, pyrimidinyl, pyridazinyl, indolyl, tetrahydroquinolyl or thiazolyl, each of which may have substituents;n is 1 or 2; or a salt. And this invention provides a safe pharmaceutical comprising the compound of the formula (I) , which has an excellent apoptosis inhibitory effect and MIF binding effect, for preventing and/or treating heart disease, nervous degenerative disease, cerebrovascular disease, central nervous infectious disease, traumatorathy, demyelinating disease, bone and articular disease, kidney disease, liver disease, osteomyelodysplasia, AIDS, cancer, and the like.

Synthesis and antienteroviral activity of a series of novel, oxime ether-containing pyridyl imidazolidinones

A series of pyridyl imidazolidinones were synthesized and their antiviral activity was evaluated in a plaque reduction assay. It was found that the pyridyl imidazolidinone with an ethyl oxime ether functionality, 8b, exhibited extremely high activity against human enterovirus 71.

Imidazolidinone compounds

This invention relates to compounds of the following formula: in which R1, R2, A1, A2, X, Y, m, n, p, x and y are as defined herein, pharmaceutical compositions comprising the compounds and use of the compounds in treating enterovirus infection.

Design, synthesis, and structure-activity relationship of pyridyl imidazolidinones: A novel class of potent and selective human enterovirus 71 inhibitors

When skeletons of Win compounds were used as templates, computer-assisted drug design led to the identification of a novel series of imidazolidinone derivatives with significant antiviral activity against enterovirus 71 (EV 71), the infection of which had

New substituted 1-(2,3-dihydrobenzo[1,4]dioxin-2-ylmethyl)piperidin-4-yl derivatives with α2-adrenoceptor antagonist activity

The emergence of a novel theory concerning the role of noradrenaline in the progression and the treatment of neurodegenerative diseases such as Parkinson's and Alzheimer's diseases has provided a new impetus toward the discovery of novel compounds acting at α2-adrenoceptors. A series of substituted 1-(2,3-dihydrobenzo[1,4]dioxin-2-ylmethyl)piperidin-4-yl derivatives bearing an amide, urea, or imidazolidinone moiety was studied. Some members of this series of compounds proved to be potent α2-adrenoceptor antagonists with good selectivity versus α1-adrenergic and D2-dopamine receptors. Particular emphasis is given to compound 33g which displays potent α2-adrenoceptor binding affinity in vitro and central effects in vivo following oral administration.